ClinicalTrials.gg
RecruitingNCT06617949Updated Nov 5, 2026

Evaluating Pain Control Strategies in Postpartum Patients on Opioid Use Disorder Medications.

An Early Phase 1 interventional study of Regional Anesthesia and Hydromorphone Patient Controlled Analgelsic in Substance Use Disorder (SUD), sponsored by Medical College of Wisconsin. Recruiting at 2 sites in United States. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Medical College of Wisconsin · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,589 studies in Substance-Related Disorders with a site in United States — 249 open to participants now, 313 under way, 4 of them phase 3. Substance-Related Disorders · United States.

Planned enrollment
1,233rd of 1,447
20 · median 104
Started
2025
with 80 others
Phase 1
131 of 1,589
14 open now
Primary completion
2027-12
later than 177 of 312 live
Registered
1,405th of 1,589
by date

Among the 1,589 studies in Substance-Related Disorders with a site in United States, this one is the 1,233rd largest by planned enrollment of the 1,447 interventional ones that give a count, is one of 81 that started in 2025, is one of 131 in phase 1, reaches primary completion later than 177 of the 312 other live ones, and was the 1,405th registered.

Substance-Related Disorders

2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

249 of the 1,589 studies in Substance-Related Disorders with a site in United States are open now. Recruiting first, the newest first:

244 more — sign in →

All 249 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,589 studies in Substance-Related Disorders with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy of three different modalities of post-operative pain control in parturient with opioid use disorders. The investigators aim to determine whether the different approach utilized show better outcomes with pain management and if there are any association with reduction of symptoms of anxiety, depression, and overall well-being.

03

Conditions studied

  • Substance Use Disorder (SUD)

Keywords

  • Pain conrtrol
  • Substance use disorder
  • Parturient
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inclusion criteria include being a parturient with Substance use disorder (SUD) and age 18-35

Exclusion criteria

Exclusion Criteria:

  • Exclusion criteria include having a diagnosed medical condition(allergies to medication, pathology such as severe aortic stenosis excluding patients from receiving an epidural etc) that will exempt patient from intervention arm of the study.
05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Transverse abdominal Plane(TAP) Block with long acting Exparel

    A subset of participants (n=15) will be divided into three different arms: A.) Postoperative Epidural infusion for 24-36hrs B.) Hydromorphone Patient Controlled Analgesia (PCA) with Preservative free Morphine via epidural for 36hrs C.) Transverse abdominal Plane(TAP) Block with long acting Exparel.

    Drug: Regional Anesthesia

  • Active comparator
    Postoperative Epidural infusion for 24-36hrs

    A subset of participants (n=15) will be divided into three different arms: A.) Postoperative Epidural infusion for 24-36hrs B.) Hydromorphone Patient Controlled Analgesia (PCA) with Preservative free Morphine via epidural for 36hrs C.) Transverse abdominal Plane(TAP) Block with long acting Exparel.

    Procedure: Epidural local anesthetic infusion

  • Active comparator
    Hydromorphone Patient Controlled Analgesia (PCA),Preservative free Morphine via epidural for 36hrs

    A subset of participants (n=15) will be divided into three different arms: A.) Postoperative Epidural infusion for 24-36hrs B.) Hydromorphone Patient Controlled Analgesia (PCA) with Preservative free Morphine via epidural for 36hrs C.) Transverse abdominal Plane(TAP) Block with long acting Exparel.

    Drug: Hydromorphone Patient Controlled Analgelsic

Interventions

  • DrugRegional Anesthesia

    Transverse abdominal Plane(TAP) Block with long acting Exparel placed by a regional anesthesiologist.

  • DrugHydromorphone Patient Controlled Analgelsic

    This group will be administered epidural PCA as a modality for pain control post cesarian section

  • ProcedureEpidural local anesthetic infusion

    Epidural group will receive pain control via a local anesthetic intermediate bolus infusion

06

What researchers measure

Primary outcomes

  1. Number of participants with Change in pain assessment scores from baseline post surgery

    Number of participants with significant change in pain assessment scores and any association with reduction of symptoms of anxiety, depression, and overall well-being.

    Time frame: immediately after the study intervention and up to post op day 2

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified patient data, statistical analysis and conclusions.

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2027, 35 months after the start.

Of 30 non-industry phase 1 interventional studies under Substance-Related Disorders, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 46. This study's planned 35 months is close to that.

Counting every sponsor, half of 54 studies reached it within 12 months; a quarter within 4 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2024
First posted
Oct 1, 2024
StartActual
Jan 16, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and date precision
1 update, last Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Minor edits only
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06617949
Responsible party
Christopher Fadumiye (Assistant Professor, Medical College of Wisconsin) — Principal investigator
First posted
Oct 1, 2024
Start date
Jan 16, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Meredith Albrecht, MD, PhD
Contact
maalbrecht@mcw.edu
414-805-8700
Christopher Fadumiye, MD
Contact
cfadumiye@mcw.edu
414-805-8700

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion